Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product ...
Abstract Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an in vitro antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs.…
related reading
- A primer on machine learning in antibody engineeringabhishaike.com
- Frontiers | Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
- Mesa — JURA Bio, Inc.jura.bio
- In vitro-engineered non-antibody protein therapeuticsncbi.nlm.nih.gov
- Boosting therapeutic potency of antibodies by taming Fc domain functions | Experimental & Molecular Medicinenature.com
- Current progress in innovative engineered antibodies | Protein & Cell | Springer Nature Linklink.springer.com
- Therapeutic Antibodies against Intracellular Tumor Antigensfrontiersin.org
- How to make an antibody - Works in Progress Magazineworksinprogress.co
- Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR - PMCncbi.nlm.nih.gov
- Antibody Structure - BioAtlabioatla.com
- Manifold Bio | Tissue-targeted medicines, designed in vivomanifold.bio
- Going Up: What's Behind the Growth in IVIG Demandbstquarterly.com